As a result, NKG2D plays a crucial role in immune activation; however, it may be downregulated due to the production of soluble NKG2DLs by tumor cells, therefore preventing NK-tumor cell association and diminishing the efficacy of CAR-NK therapy (2, 27). Here, KLRK1 is linked to neoplasm.